Navigation Links
'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients
Date:3/20/2009

A campaign which will reduce mortality in patients with acute coronary syndromes has been launched today by a coalition which includes the ESC Working Group on Acute Cardiac Care and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). "Stent 4 Life" is a project designed to encourage the wider use of reperfusion therapy with percutaneous coronary interventions (PCI, with balloon angioplasty and stent) in Europe. According to a new report introducing the campaign, it is the "unpredictable bursts" in coronary artery disease which lead to sudden ischaemic death, heart attack and unstable angina, and with them a sharp increase in mortality rate to more than 10%.(1)

Indeed, new European guidelines on the management of heart attack emphasise not only speed of action but also the importance of reperfusion to restore blood flow to the heart and improve survival rates.(2)

The Stent 4 Life campaign particularly addresses treatment of a common type of classical heart attack known as STEMI (ST-segment elevation acute myocardial infarction), a reference to its appearance on an ECG. Around one-third of all acute coronary events are diagnosed as STEMI, and the greater application of PCI (to rates above 600 per million population) "would enable us to address the needs of most patients suffering from STEMI across Europe".

The report adds: "The mission of the Stent 4 Life coalition is to promote the lifesaving indications of PCI, implying that priority will be given to targeting invasive resources to those patient groups who will benefit the most. Rather than attempting to enforce top down directives, the program will rely entirely on national Interventional Working Groups and Societies. Synergy, rather than competition, with existing initiatives will be the goal."

"There is first class evidence that primary PCI for acute STEMI is now the gold standard of care," says ESC spokesperson Professor Jean Fajadet, from the Clinique Pasteur in Toulouse, France. "But what we have seen is that its use in STEMI patients varies throughout Europe. In those countries with a high rate of PCI such as Denmark, Poland, Czech Republic and the Netherlands the number of untreated patients is low. Conversely, in countries with a low use of primary PCI the number of untreated patients is high."

The Stent 4 Life campaign aims to identify those countries where the use of primary PCI can be encouraged, and thereby the quality of care improved. The basis for the campaign is a questionnaire study with local cardiac societies in Europe and an assessment of individual requirements for a national programme. The recently announced National Infarct Angioplasty Project in the UK is one such action plan.

"We are convinced that this action will be of benefit to all," says the report. "Engaging in Stent 4 Life is simply the right thing to do, and at this early stage, we trust and rely on the active involvement of the entire interventional community."

Current registry data suggest that around 20-30 per cent of all STEMI patients in Europe still receive no reperfusion therapy. However, the report suggests that adherence to the guidelines and a greater use of primary PCI could dramatically improve STEMI patient survival.


'/>"/>

Contact: ESC Press Office
press@escardio.org
0033-492-948-627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
2. Bioabsorbable stents show promise
3. Drugs Before Stents for Stable Heart Disease, Study Says
4. Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R)
5. Drug-Eluting Stents Show Promise for Leg Arteries
6. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
7. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
8. SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents
9. Is Bypass Truly Better than Stenting?
10. Noninvasive screening test may detect narrowing in intracranial stents
11. Volunteer work in grade schools produces persistent health benefit for older black women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... ... 27, 2017 , ... Adding to its expanding portfolio of ... and NEJM Journal Watch, announces the release of NEJM Knowledge+ Pediatrics Board ... of pediatricians from leading medical centers. The content was then reviewed and approved ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical ... Cambridge academic scientists through ... Milner Therapeutics Institute today announces Elysium Health as a partner ... investment for collaborative projects with academic researchers in ... the first major research investment outside the U.S. for the ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
(Date:3/27/2017)... VANCOUVER, British Columbia , March 27, 2017 /PRNewswire/ ... of Directors has appointed William "Bill" Dubiel as President ... Dubiel was also elected to the Board of Directors ... serve as the Executive Chairman of LightIntegra. ... become LightIntegra,s next President and Chief Executive Officer. We,ve ...
Breaking Medicine Technology: